Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
Kaufmann M., von Minckwitz G., Bear HD., Buzdar A., McGale P., Bonnefoi H., Colleoni M., Denkert C., Eiermann W., Jackesz R., Makris A., Miller W., Pierga JY., Semiglazov V., Schneeweiss A., Souchon R., Stearns V., Untch M., Loibl S.
Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.